Phaseline

Targets › IGSF8

IGSF8 (Immunoglobulin superfamily member 8): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Ophthalmology; next expected readout Jan 2027.

Member of the immunoglobulin superfamily (IgSF) that links tetraspanin-enriched microdomains to the actin cytoskeleton and plays several important roles in innate and adaptive immunity. Acts as an inducible receptor of HSPA8 on dendritic cells to enhance the CCL21/SLC-dependent migration of activated mature dendritic cells while attenuating their antigen-specific stimulatory capacities. (UniProt, Q969P0)

Open in Phaseline: the race on IGSF8, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AmgenAMG 732
Insulin Growth Factor-1 Receptor (IGF-1R) pathway inhibitor via IGSF8 binding
IGSF8Phase 2Thyroid Eye DiseaseJan 2027

Conditions

Thyroid Eye Disease (2)

Modalities

small molecule (1)

Companies

Amgen (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.